Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00564928 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer
A Phase 2 study of Prostate Cancer and Prostatic Neoplasms, sponsored by Infinity Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
- 10
- Study locations
NCT00564928: Completed Phase 2 study of Prostate Cancer and Prostatic Neoplasms, sponsored by Infinity Pharmaceuticals.
NCT00564928 is a Phase 2 study of Prostate Cancer and Prostatic Neoplasms that has completed, run by Infinity Pharmaceuticals. The registered enrollment target is 19 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (97% lower). The trial reports 10 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00564928, a Phase 2 study of Prostate Cancer and Prostatic Neoplasms, has completed, sponsored by Infinity Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
- 10
- Study locations
Study Summary
To determine: * Anti-tumor activity of IPI-504 in 2 groups of subjects with hormone resistant prostate cancer. * Group A - subjects who have not previously received chemotherapy * Group B - sujects who have received prior chemotherapy or could not tolerate chemotherapy. * Clinical response will be determined by PSA and radiological response
Conditions Studied
Interventions
- DRUG IPI-504
Study Locations (10)
Massachusetts
- Dana-Farber Cancer Institute - Boston
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
California
- San Bernardino Urological Associates - San Bernardino
- Stanford University Medical Center - Stanford
Colorado
- University of Colorado at Denver - Denver
Georgia
- MCG Cancer Center - Augusta
Illinois
- University of Chicago Hospitals - Chicago
Michigan
- Wayne State University - Detroit
Texas
- Parkland Hospital - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2007-11 |
| Est. Completion | 2010-07 |
| Phase | Phase 2 |
What the finished NCT00564928 record still lists
NCT00564928 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (97% lower).
The record links to 3 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which IPI-504 is the first listed.
NCT00564928 lists 10 locations in 7 states (Massachusetts, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT00564928 about?
NCT00564928 is a clinical study titled "A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer". To determine: * Anti-tumor activity of IPI-504 in 2 groups of subjects with hormone resistant prostate cancer. * Group A - subjects who have not previously received chemotherapy * Group B - sujects who have received prior chemotherapy or could not tolerate chemotherapy. * Clinical response will be ...
What is the current status of trial NCT00564928?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2007-11. Estimated completion is 2010-07.
What conditions does trial NCT00564928 study?
This clinical trial studies the following conditions: Prostate Cancer, Prostatic Neoplasms, Cancer of the Prostate.
What interventions are being tested in trial NCT00564928?
The interventions under investigation include: IPI-504 (DRUG).
Who is sponsoring clinical trial NCT00564928?
This trial is sponsored by Infinity Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00564928 being conducted?
This trial has 10 study locations across California, Colorado, Georgia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00564928's enrollment target sits among peer trials
19 668th of 735 higher than 62 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia